184 related articles for article (PubMed ID: 22350024)
1. Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predictive value of immunohistochemically defined subtypes.
Nelli F; Moscetti L; Natoli G; Massari A; D'Auria G; Chilelli M; Fabbri MA; Frittelli P; Ruggeri EM
Int J Clin Oncol; 2013 Apr; 18(2):343-9. PubMed ID: 22350024
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer.
Loesch D; Asmar L; McIntyre K; Doane L; Monticelli M; Paul D; Vukelja S; Orlando M; Vaughn LG; Zhan F; Boehm KA; O'Shaughnessy JA
Clin Breast Cancer; 2008 Apr; 8(2):178-86. PubMed ID: 18621615
[TBL] [Abstract][Full Text] [Related]
3. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
Trials; 2015 Dec; 16():575. PubMed ID: 26673577
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer.
Laessig D; Stemmler HJ; Vehling-Kaiser U; Fasching PA; Melchert F; Kolbl H; Stauch M; Maubach P; Scharl A; Morack G; Meerpohl H; Weber B; Kalischefski B; Heinemann V
Oncology; 2007; 73(5-6):407-14. PubMed ID: 18515981
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.
Hussain MH; MacVicar GR; Petrylak DP; Dunn RL; Vaishampayan U; Lara PN; Chatta GS; Nanus DM; Glode LM; Trump DL; Chen H; Smith DC;
J Clin Oncol; 2007 Jun; 25(16):2218-24. PubMed ID: 17538166
[TBL] [Abstract][Full Text] [Related]
6. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
Tan AR; Wright GS; Thummala AR; Danso MA; Popovic L; Pluard TJ; Han HS; Vojnović Ž; Vasev N; Ma L; Richards DA; Wilks ST; Milenković D; Yang Z; Antal JM; Morris SR; O'Shaughnessy J
Lancet Oncol; 2019 Nov; 20(11):1587-1601. PubMed ID: 31575503
[TBL] [Abstract][Full Text] [Related]
7. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
8. Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline- and taxane-pretreated breast cancer patients: a phase II study.
Maisano R; Zavettieri M; Azzarello D; Raffaele M; Maisano M; Bottari M; Nardi M
J Chemother; 2011 Feb; 23(1):40-3. PubMed ID: 21482494
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.
Kontopodis E; Kentepozidis N; Christophyllakis Ch; Boukovinas I; Kalykaki A; Kalbakis K; Vamvakas L; Agelaki S; Kotsakis A; Vardakis N; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2015 Jan; 75(1):153-60. PubMed ID: 25398698
[TBL] [Abstract][Full Text] [Related]
10. Iniparib plus chemotherapy in metastatic triple-negative breast cancer.
O'Shaughnessy J; Osborne C; Pippen JE; Yoffe M; Patt D; Rocha C; Koo IC; Sherman BM; Bradley C
N Engl J Med; 2011 Jan; 364(3):205-14. PubMed ID: 21208101
[TBL] [Abstract][Full Text] [Related]
11. Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial.
Yardley DA; Ward PJ; Daniel BR; Eakle JF; Lamar RE; Lane CM; Hainsworth JD
Clin Breast Cancer; 2016 Oct; 16(5):349-355. PubMed ID: 27340049
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer.
Yardley DA; Burris HA; Simons L; Spigel DR; Greco FA; Barton JH; Shipley D; Drosick D; Hainsworth JD
Clin Breast Cancer; 2008 Oct; 8(5):425-31. PubMed ID: 18952556
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
[TBL] [Abstract][Full Text] [Related]
14. Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles.
Vernieri C; Prisciandaro M; Milano M; Cona MS; Maggi C; Brambilla M; Mennitto A; Fabbroni C; Farè E; Cresta S; Celio L; Mariani G; Bianchi G; Capri G; de Braud F
Clin Breast Cancer; 2019 Apr; 19(2):e306-e318. PubMed ID: 30635175
[TBL] [Abstract][Full Text] [Related]
15. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial.
Iyengar NM; Smyth LM; Lake D; Gucalp A; Singh JC; Traina TA; DeFusco P; Fornier MN; Goldfarb S; Jhaveri K; Modi S; Troso-Sandoval T; Patil S; Ulaner GA; Jochelson M; Norton L; Hudis CA; Dang CT
JAMA Netw Open; 2019 Nov; 2(11):e1916211. PubMed ID: 31774522
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer.
O'Shaughnessy JA; Vukelja S; Marsland T; Kimmel G; Ratnam S; Pippen JE
Clin Breast Cancer; 2004 Jun; 5(2):142-7. PubMed ID: 15245619
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients.
Ozdemir N; Aksoy S; Sendur MA; Akinci MB; Yazici O; Budakoglu B; Abali H; Oksuzoglu B; Zengin N
J BUON; 2013; 18(4):831-7. PubMed ID: 24344005
[TBL] [Abstract][Full Text] [Related]
19. In vitro chemoresponse assay based on the intrinsic subtypes in breast cancer.
Gwe Ahn S; Ah Lee S; Woo Lee H; Min Lee H; Jeong J
Jpn J Clin Oncol; 2014 Jul; 44(7):624-31. PubMed ID: 24803548
[TBL] [Abstract][Full Text] [Related]
20. Correlation between ER, PR, HER-2, Bcl-2, p53, proliferative and apoptotic indexes with HER-2 gene amplification and TOP2A gene amplification and deletion in four molecular subtypes of breast cancer.
Mitrović O; Čokić V; Đikić D; Budeč M; Vignjević S; Subotički T; Gulan M; Radović S; Furtula S
Target Oncol; 2014 Dec; 9(4):367-79. PubMed ID: 24272208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
